Literature DB >> 33836870

Early Adaptive Natural Killer Cell Expansion Is Associated with Decreased Relapse After Autologous Transplantation for Multiple Myeloma.

Aimee M Merino1, Rohtesh S Mehta2, Xianghua Luo3, Hansol Kim4, Todd De For3, Murali Janakiram4, Sarah Cooley5, Rose Wangen4, Frank Cichocki4, Daniel J Weisdorf4, Jeffrey S Miller4, Veronika Bachanova4.   

Abstract

Adaptive natural killer (NK) cells are long-lived and exhibit properties of immunologic memory against cytomegalovirus (CMV). We previously reported that expansion of adaptive NK cells after CMV reactivation in recipients of allogeneic hematopoietic cell transplantation (HCT) was associated with a lower rate of relapse of acute myelogenous leukemia. In the present study, we examined the impact of adaptive NK cell expansion in a cohort of 110 individuals who underwent autologous HCT (AHCT) for a lymphoid malignancy (lymphoma or multiple myeloma [MM]). In this cohort, higher absolute numbers of adaptive NK cells (>1.58/μL) at day 28 post-AHCT were associated with significantly decreased risk of relapse in patients with MM. No significant association was seen in patients with lymphoma. Further stratification of MM patients by CMV serostatus found a strong protective effect of adaptive NK cells only in CMV-seropositive individuals. These findings suggest that strategies to increase adaptive NK cells after AHCT may be a therapeutic option in patients with MM.
Copyright © 2020 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adaptive natural killer cells; Autologous transplant; Cytomegalovirus; Multiple myeloma

Mesh:

Year:  2020        PMID: 33836870     DOI: 10.1016/j.jtct.2020.10.023

Source DB:  PubMed          Journal:  Transplant Cell Ther        ISSN: 2666-6367


  4 in total

1.  Diminished cell proliferation promotes natural killer cell adaptive-like phenotype by limiting FcεRIγ expression.

Authors:  Avishai Shemesh; Yapeng Su; Daniel R Calabrese; Daniel Chen; Janice Arakawa-Hoyt; Kole T Roybal; James R Heath; John R Greenland; Lewis L Lanier
Journal:  J Exp Med       Date:  2022-09-06       Impact factor: 17.579

2.  Long-term outcome of immunologic autograft engineering.

Authors:  Luis F Porrata; David J Inwards; Stephen M Ansell; Ivana N Micallef; Patrick B Johnston; Jose C Villasboas; Jonas Paludo; Svetomir N Markovic
Journal:  EJHaem       Date:  2022-02-24

3.  CMV Triplex Vaccine to Enhance Adaptive NK and T-cell Reconstitution After Autologous Hematopoietic Cell Transplantation.

Authors:  Armin Rashidi; Corinna La Rosa; Julie Curtsinger; Qing Cao; Qiao Zhou; Chetan Raj Lingaraju; Daniel J Weisdorf; Frank Cichocki; Jeffrey S Miller; Don J Diamond
Journal:  Transplant Cell Ther       Date:  2022-03-08

4.  NK Cell Reconstitution After Autologous Hematopoietic Stem Cell Transplantation: Association Between NK Cell Maturation Stage and Outcome in Multiple Myeloma.

Authors:  Ane Orrantia; Iñigo Terrén; Gabirel Astarloa-Pando; Carmen González; Alasne Uranga; Juan J Mateos-Mazón; Juan C García-Ruiz; Marta Riñón; Mercedes Rey; Silvia Pérez-Fernandez; Olatz Zenarruzabeitia; Francisco Borrego
Journal:  Front Immunol       Date:  2021-10-05       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.